Details of the Drug Reposition

General Information of This Drug (ID: DMKI2XC)

Drug Name
Sulfacytine   DMKI2XC
Synonyms
Renoquid; Sulfacitina; Sulfacitine; Sulfacitinum; CL 636; Renoquid (TN); Sulfacitina [INN-Spanish]; Sulfacitinum [INN-Latin]; Sulfacytine (USAN); Sulfacytine [USAN:BAN]; N-Sulfanilyl-l-ethylcytosine; Nl-sulfanilyl-1-ethylcytosine; N(sup 1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; N(sup1)-(1-Ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)sulfanilamide; Sulfanilamide, N1-(1-ethyl-1,2-dihydro-2-oxo-4-pyrimidinyl)-(8CI); 1-Ethyl N4-sulfanilylcytosin; 1-Ethyl-N-sulfanilylcytosine; 4-amino-N-(1-ethyl-2-oxo-1,2-dihydropyrimidin-4-yl)benzenesulfonamide; 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cystitis DIS2D4B9 GC00 Approved [1]
Urinary tract infection DISMT6UV GC08 Approved [1]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 017569.